Graduate Studies Faculty

« Back to Search List



Aaron Janowsky, Ph.D.

Director, The Methamphetamine Abuse Research Center
Professor, Depts. of Psychiatry and Behavioral Neuroscience
V.A. Research Career Scientist
Admin Unit: SOM-Psychiatry Department
Programs:
Behavioral Neuroscience
Research Interests:
Brain, neurotransmitter transporter function and regulation, G-protein coupled receptors, receptor regulation, signal transduction systems, neuropsychiatric disorders, schizophrenia, addiction, methamphetamine, cocaine, pharmacotherapy development, behavioral, Neurobiology of Disease » PubMed Listing
Preceptor Rotations
Dr. Janowsky has not indicated availability for preceptor rotations at this time.
Faculty Mentorship
Dr. Janowsky has not indicated availability as a mentor at this time.
Profile

Summary of Current Research  

My laboratory is involved in characterizing drug interactions with neurotransmitter transporters and receptors. A major goal is to identify potential therapeutic agents for the treatment of neuropsychiatric disorders including Parkinson's disease, alcohol and drug abuse, depression, and schizophrenia. Methods we use include determining the effects of drugs on radioligand binding to, on neurotransmitter uptake and release by cells expressing cloned DNA for the respective human transporters, and on receptor activation and second messenger system function.    

In addition, we are characterizing recently-discovered receptor/second messenger systems that may play a role in the development of symptoms of potential subtypes of schizophrenia, as well as the role of exogenous substances on disease development .  Alteration of these systems may serve as medical, as opposed to behavioral, diagnostic criteria for the disorder(s).   

Recent Publications    

Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A. Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol. {Epub ahead of print] 2013

Keith DJ, Wolfrum K, Eshleman AJ, Janowsky A.  Melittin initiates dopamine transporter internalization and recycling in transfected HEK-293 cells. Eur J Pharmacol. 690(1-3):13-21. (2012)

Cashman JR, Okolotowicz K, Cerny M, Johnson R, Janowsky A, Azar MR. Substituted heteroaromatic compounds: effect on nicotine self-administration in rats. Psychopharmacology (Berl).221(4):637-48. (2012)

Gatch MB, Forster MJ, Janowsky A, Eshleman AJ. Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther. 338(1):280-9. (2011)

Keith DJ, Eshleman AJ, Janowsky A. Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins. Eur J Pharmacol. 650(2-3):501-10. (2011)

Education  

Ph.D., Vanderbilt University, 1982